Screener
Apogee Therapeutics, Inc. APGE Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Research and development (1) | $60,819 | $46,387 |
| General and administrative | 21,953 | 16,709 |
| Total operating expenses | 82,772 | 63,096 |
| Loss from operations | (82,772) | (63,096) |
| Other income, net: | ||
| Interest income, net | 8,740 | 7,840 |
| Total other income, net | 8,740 | 7,840 |
| Net loss before taxes | (74,032) | (55,256) |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s operating income?
- Apogee Therapeutics, Inc. (APGE) reported operating income of -$82.77M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s operating income changed year-over-year?
- Apogee Therapeutics, Inc.'s operating income decreased by 31.2% year-over-year, from -$63.1M to -$82.77M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s operating income?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s operating income has grown at a 75.2% compound annual growth rate (CAGR), from -$93M to -$285.6M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Apogee Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude